Myeloma Therapy: Pursuing the Plasma Cell (Contemporary Hematology)

Therapeutic options for patients with myeloma have radically changed over the past ten years. Myeloma Therapy: Pursuing the Plasma Cell provides updated various treatment options for patients with myeloma, with focus on the emerging and speculative aspects of myeloma therapy. Written by clearly acknowledged leaders in the field of myeloma therapy and research, Myeloma Therapy: Pursuing the Plasma Cell presents significant material on the biology and potential agents used to address specific signaling pathways, all of which are critical to myeloma biology and therapy. State of the art information from many of the leaders in the plasma cell disorders world includes disease pathogenesis and biology, chemotherapy based approaches, immune based therapies, currently approved novel agents, developing targets, supportive care, and other plasma cell disorders. Myeloma Therapy: Pursuing the Plasma Cell is a comprehensive collection and tremendous source in this time of rapid change in clinical and preclinical disease knowledge. Front Matter....Pages i-xvi Staging in Multiple Myeloma....Pages 3-7 Epidemiology of Multiple Myeloma....Pages 9-22 Basic Biology of Plasma Cell Dyscrasias: Focus on the Role of the Tumor Microenviroment....Pages 23-39 Biology-Based Classification and Staging of Multiple Myeloma....Pages 41-56 Cytogenetic Abnormalities in Multiple Myeloma: The Importance of FISH and Cytogenetics....Pages 57-76 Role of Autologous Stem Cell Transplantation in Multiple Myeloma....Pages 79-90 Maintenance Therapy in Multiple Myeloma....Pages 91-98 Therapy for Patients not Eligible for Autologous Transplant....Pages 99-112 Current Role of Anthracyclines in the Treatment of Multiple Myeloma....Pages 113-121 Allogeneic Transplantation for Multiple Myeloma....Pages 125-142 Immunobiology and Immunotherapy of Multiple Myeloma....Pages 143-166 Antibody and Other Immune-Based Therapies for Myeloma....Pages 167-202 Thalidomide in Patients with Relapsed Multiple Myeloma....Pages 205-227 Thalidomide: Induction Therapy....Pages 229-237 The Role of Bortezomib in the Treatment of Relapsed and Refractory Multiple Myeloma....Pages 239-252 Bortezomib as Induction Therapy in Patients with Multiple Myeloma....Pages 253-263 Lenalidomide in Relapsed or Refractory Multiple Myeloma....Pages 265-277 Lenalidomide for Initial Therapy of Newly Diagnosed Multiple Myeloma....Pages 279-288 The Role of Heat Shock Protein 90 as a Therapeutic Target for Multiple Myeloma....Pages 291-308 The PI3 Kinase/Akt Pathway as a Therapeutic Target in Multiple Myeloma....Pages 309-322 The Mammalian Target of Rapamycin and Multiple Myeloma....Pages 323-330 CDK Inhibitors in Multiple Myeloma....Pages 331-363 Fibroblast Growth Factor Receptor 3 and Multiple Myeloma....Pages 365-378 Histone Deacetylase Inhibitors in Multiple Myeloma....Pages 379-392 Death Receptors in Multiple Myeloma and Therapeutic Opportunities....Pages 393-419 Proteasome Inhibitors as Therapy in Multiple Myeloma....Pages 421-432 Pathophysiology of Bone Disease in Multiple Myeloma....Pages 435-454 Anemia and Erythropoeitic Growth Factors in Multiple Myeloma....Pages 455-468 Percutaneous Vertebroplasty and Balloon Kyphoplasty for the Treatment of Acute Painful Pathologic and Nonpathologic Fractures....Pages 469-489 The Role of Anatomic and Functional Imaging in Myeloma....Pages 491-498 Management of Multiple Myeloma Patients with Renal Dysfunction....Pages 499-516 Waldenstrom's Macroglobulinemia....Pages 519-550 AL (Immunoglobulin Light-Chain) Amyloidosis....Pages 551-569 POEMS Syndrome and Other Atypical Plasma Cell Disorders....Pages 571-623 Monoclonal Gammopathy of Undetermined Significance....Pages 625-649 Back Matter....Pages 651-663 Therapeutic options for patients with myeloma have dramatically changed over the past 10 years. Beginning with the advances in therapy resulting from the use of high-dose therapy and autologous bone marrow or stem cell tra- plant, we have more than doubled the median survival for patients as a whole, and have now have a wealth of different biology -based treatment approaches for our patients in all disease stages. This book represents state-of-the-art information from many of the leaders in the plasma cell disorders world. Sections focusing on disease pathogenesis and biology, chemotherapy-based approaches, immune -based therapies, currently approved novel agents, developing targets, supportive care, and other plasma cell disorders provides a comprehensive collection and an excellent resource in this time of rapid change in clinical and preclinical disease knowledge. It is important to realize that these changes did not occur in a vacuum. Partnerships between academic institutions, the pharmaceutical industry, patient advocacy groups, the National Cancer Institute, community onco- gists, and ultimately our patients worked closely together to realize these advances, and to effect the radical changes in therapy we have witnessed over the past few years. This book would not have been possible without contri- tions from each of the gifted scientists and clinicians who worked tirelessly to prepare their individual chapters all the while maintaining commitment to the scientific and clinical mission of advancing care. Therapeutic options for patients with myeloma have radically changed over the past ten years. Myeloma Therapy: Pursuing the Plasma Cell provides various updated treatment options for patients with myeloma, with focus on the emerging and speculative aspects of myeloma therapy. Written by clearly acknowledged leaders in the field of myeloma therapy and research, Myeloma Therapy: Pursuing the Plasma Cell presents significant material on the biology and potential agents used to address specific signaling pathways, all of which are critical to myeloma biology and therapy. State of the art information from many of the leaders in the plasma cell disorders world includes disease pathogenesis and biology, chemotherapy based approaches, immune based therapies, currently approved novel agents, developing targets, supportive care, and other plasma cell disorders. Myeloma Therapy: Pursuing the Plasma Cell is a comprehensive collection and indispensable resource in this time of rapid change in clinical and preclinical disease knowledge Therapeutic options for patients with myeloma have radically changed over the past ten years. Beginning with the advances in therapy resulting from the use of high dose therapy and autologous bone marrow or stem cell transplant, we have more than doubled the median survival for patients as a whole, and have now a wealth of different biology based treatment approaches for our patients in all disease stages. The purpose of this book is to update the various treatment options for patients with myeloma, as well as to focus on the emerging and speculative aspects of myeloma therapy. This will require review of basic mechanisms of disease as well as further discussions on how these mechanisms can best be targeted. While there will be text covering most areas of myeloma therapy, the prime focus of the book will be the novel agents currently in testing as well as potential future novel targets and agents Presents various treatment options for patients with myeloma. This book reviews basic mechanism of the disease and shows how these mechanisms can best be targeted Edited By Sagar Lonial. Includes Bibliographical References And Index.